Blepharospasm

Last updated
Blepharospasm
Other namesEye dystonia, Eye twitching, Eye spasm
Pronunciation
Specialty Neurology, ophthalmology

Blepharospasm is a neurological disorder characterized by intermittent, involuntary spasms and contractions of the orbicularis oculi (eyelid) muscles around both eyes. [1] [2] [3] [4] These result in abnormal twitching or blinking, and in the extreme, sustained eyelid closure resulting in functional blindness.

Contents

The word blepharospasm is derived from the Greek: βλέφαρον / blepharon, eyelid, and σπασμός / spasmos, spasm, an uncontrolled muscle contraction. The condition should be distinguished from the more common, and milder, involuntary quivering of an eyelid, known as myokymia or fasciculation.

Blepharospasm is one form of a group of movement disorders called dystonia. [4] It may be a primary or secondary disorder. The primary disorder is benign essential blepharospasm, in which term the qualifier essential indicates that the cause is unknown. Blepharospasm may occur as secondary to conditions including dry eyes and other specific ocular disease or conditions, Meige's Syndrome and other forms of dystonia, and Parkinson's Disease and other movement disorders. [3]

Blepharospasm occurs in middle age and is more frequent among women than men. The most common treatments are medication and periodic injections of botulinum toxin into the eyelid muscles.

Epidemiology

Blepharospasm is a fairly rare disease. Estimates of incidence and prevalence vary, tending to be higher in population studies than service studies, [5] likely because of delays in diagnosis. [4] In the United States, approximately 2,000 new cases of blepharospasm are diagnosed each year. [6] Estimates of incidence per million persons-years range from 14.5 in Northern California [7] to 100 in Taiwan. [8] Estimates of prevalence per million range from 12 in Olmsted County, Minnesota [9] to 133 in Puglia, Southern Italy. [10]

The onset of blepharospasm tends to be during the ages 40-60. [8] [10] [11] The condition is roughly more than twice as frequent among females than males, [7] [8] [11] which may be related to menopause and hormone treatments. [12] [13] In Taiwan, the condition is more frequent among white- than blue-collar workers. [8]

Signs and symptoms

Blepharospasm usually begins with occasional twitches of both eyelids, which progress over time to forceful and frequent spasms and contractions of the eyelids. In severe episodes, the patient cannot open their eyelids (apraxia), which severely limits their daily activities. Prolonged closure of the eyelids may result in functional blindness. [4]

Patients suffering from blepharospasm also report sensory symptoms including sensitivity to light, [14] [15] dry eyes, [16] and burning sensation and grittiness in the eyes. [4] Although such symptoms tend to precede the onset of the blepharospasm, they may both be due to a common third factor. [17]

Typically, the symptoms---spasms and contractions of the eyelids---tend to worsen when the patient relaxes but abate during sleep. [18] The symptoms may be temporarily alleviated by sensory tricks (geste antagoniste) including stretching or rubbing the eyebrows, eyelids, or forehead, [19] and singing, talking, or humming. [20] Blepharospasm is aggravated by fatigue, stress, and environmental factors such as wind or air pollution. [21]

Although blepharospasm is defined as a bilaterally symmetric disorder that affects both eyes, some research has reported unilateral onset. [11] [22]

Causes

Historically, it was believed that blepharospasm was due to the abnormal functioning of the brain's basal ganglia. [23] The basal ganglia are structures in the brain that are involved in the regulation of motor and reward functions.

However, blepharospasm is now known to involve several regions of the brain and to be a multifactorial condition in which "one or several as yet unknown genes together with epigenetic and environmental factors combine to reach the threshold that induces the disease". [3]

Blepharospasm is often associated with dry eyes, but the causal mechanism is still not clear. [16] [8] Research in New York and Italy suggests that increased blinking (which may be triggered by dry eyes) leads to blepharospasm. [24] [25] A case control study in China found that blepharospasm aggravated dry eyes. [26]

Blepharospasm may be associated with dystonia in other parts of the body, particularly Meige's Syndrome. [27] [28] [4] Blepharospasm may be associated with Parkinson's Disease, but the causal mechanism is still not clear. [29] [30] In rare cases, blepharospasm is associated with multiple sclerosis. [31] [32]

Some drugs can induce blepharospasm, including those used to treat depression [33] [34] and Parkinson's disease. [35] Hormone replacement therapy for women going through menopause has been found to be associated with dry eyes, [13] which in turn is associated with blepharospasm.

Blepharospasm can be caused by concussions in some rare cases, when a blow to the back of the head damages the basal ganglia. [36]

Blepharospasm is associated with exposure to the sun. [37]

Diagnosis

No laboratory tests exist with which to definitively diagnose blepharospasm. Historically, the condition was frequently misdiagnosed, [18] often as a psychiatric condition. [6]

Diagnosis of blepharospasm has been enhanced by the proposal of objective diagnostic criteria that start from "stereotyped, bilateral and synchronous orbicularis oculi spasms" and proceed to the identification of a "sensory trick" or "increased blinking". [38] The criteria have been validated across multiple ethnicities in multiple centers. [39]

Treatment

Standard first line treatments of blepharospasm are oral medication and periodic injections of botulinum toxin.

Drugs used to treat blepharospasm are anticholinergics, benzodiazepines, baclofen, and tetrabenazine. [40] The proportion of patients who benefited from anticholinergics ranged from 1 in 9 in Oregon [41] to 1 in 5 in England. [11] Besides failing to resolve the blepharospasm, some drugs present the risk of side effects. In Japan, use of etizolam and benzodiazepine was associated with the development of blepharospasm. [33] [34] As an alternative to anticholinergics and psychotropics, a case report from Sri Lanka suggests treatment with Mosapride. [42]

The main first-line therapy is periodic injections of botulinum toxin type A to induce localized, partial paralysis of the eyelid muscles. [43] [44] Injections are generally administered at intervals of around 10 weeks, with variations based on patient response and usually give fairly quick relief from the muscle spasms. An English study reported that 118 (78%) of 151 patients experienced significant relief of symptoms for a mean duration of 9.2 weeks. [11] However, in a minority of patients, the injections do not provide any symptomatic relief. Injections of botulinum toxin may diminish in effectiveness with prolonged use and require increased dosage. [45] Injections of botulinum toxin increase the risk of visual complaints and ptosis (eyelid droop). [43]

Patients who do not respond well to medication or botulinum toxin injections are candidates for surgical therapy. The most effective surgical treatment has been protractor myectomy, the removal of muscles responsible for eyelid closure. [46]

Several complementary therapies simulate sensory tricks. One is to attach a device to spectacle frames to press on the patient's temple. [47] Another is the application of thin cosmetic tapes to the forehead and eyebrows. [48]

Another complementary therapy is retraining the brain to "rewire" itself and eliminate dystonic movements. The work of Joaquin Farias has shown that sensorimotor retraining activities and proprioceptive stimulation can induce neuroplasticity, making it possible for patients to recover substantial function that was lost due to blepharospasm. [49] [50]

Patients suffering from blepharospasm may get relief by wearing spectacles fitted to lift the upper eyelid. [40]

Research

The U.S. National Library of Medicine maintains a register of clinical trials of therapies to treat blepharospasm.

Multimedia

Blepharospasm Research Foundation

Neuroplasticity training

Related Research Articles

<span class="mw-page-title-main">Essential tremor</span> Movement disorder that causes involuntary tremors

Essential tremor (ET), also called benign tremor, familial tremor, and idiopathic tremor, is a medical condition characterized by involuntary rhythmic contractions and relaxations of certain muscle groups in one or more body parts of unknown cause. It is typically symmetrical, and affects the arms, hands, or fingers; but sometimes involves the head, vocal cords, or other body parts. Essential tremor is either an action (intention) tremor—it intensifies when one tries to use the affected muscles during voluntary movements such as eating and writing—or it is a postural tremor, present with sustained muscle tone. This means that it is distinct from a resting tremor, such as that caused by Parkinson's disease, which is not correlated with movement.

<span class="mw-page-title-main">Botulinum toxin</span> Neurotoxic protein produced by Clostridium botulinum

Botulinum toxin, or botulinum neurotoxin, is a highly potent neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes. Botulinum toxin is an acetylcholine release inhibitor and a neuromuscular blocking agent.

<span class="mw-page-title-main">Parkinsonism</span> Medical condition

Parkinsonism is a clinical syndrome characterized by tremor, bradykinesia, rigidity, and postural instability. Both hypokinetic as well as hyperkinetic features are displayed by Parkinsonism.These are the four motor symptoms found in Parkinson's disease (PD) – after which it is named – dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD), and many other conditions. This set of symptoms occurs in a wide range of conditions and may have many causes, including neurodegenerative conditions, drugs, toxins, metabolic diseases, and neurological conditions other than PD.

<span class="mw-page-title-main">Dystonia</span> Neurological movement disorder

Dystonia is a neurological hyperkinetic movement disorder in which sustained or repetitive muscle contractions occur involuntarily, resulting in twisting and repetitive movements or abnormal fixed postures. The movements may resemble a tremor. Dystonia is often intensified or exacerbated by physical activity, and symptoms may progress into adjacent muscles.

<span class="mw-page-title-main">Hyperkinesia</span> Excessive movements due to basal ganglia dysfunction

Hyperkinesia refers to an increase in muscular activity that can result in excessive abnormal movements, excessive normal movements, or a combination of both. Hyperkinesia is a state of excessive restlessness which is featured in a large variety of disorders that affect the ability to control motor movement, such as Huntington's disease. It is the opposite of hypokinesia, which refers to decreased bodily movement, as commonly manifested in Parkinson's disease.

<span class="mw-page-title-main">Palatal myoclonus</span> Medical condition

Palatal myoclonus is a rare condition in which there are rhythmic jerky movements or a rapid spasm of the palatal muscles. Chronic clonus is often due to lesions of the central tegmental tract.

Neuro-ophthalmology is an academically-oriented subspecialty that merges the fields of neurology and ophthalmology, often dealing with complex systemic diseases that have manifestations in the visual system. Neuro-ophthalmologists initially complete a residency in either neurology or ophthalmology, then do a fellowship in the complementary field. Since diagnostic studies can be normal in patients with significant neuro-ophthalmic disease, a detailed medical history and physical exam is essential, and neuro-ophthalmologists often spend a significant amount of time with their patients.

Hemifacial spasm (HFS) is a rare neuromuscular disease characterized by irregular, involuntary muscle contractions (spasms) on one side (hemi-) of the face (-facial). The facial muscles are controlled by the facial nerve, which originates at the brainstem and exits the skull below the ear where it separates into five main branches.

Torsion dystonia, also known as dystonia musculorum deformans, is a disease characterized by painful muscle contractions resulting in uncontrollable distortions. This specific type of dystonia is frequently found in children, with symptoms starting around the ages of 11 or 12. It commonly begins with contractions in one general area such as an arm or a leg that continue to progress throughout the rest of the body. It takes roughly 5 years for the symptoms to completely progress to a debilitating state.

<span class="mw-page-title-main">Spasmodic torticollis</span> Medical condition

Spasmodic torticollis is an extremely painful chronic neurological movement disorder causing the neck to involuntarily turn to the left, right, upwards, and/or downwards. The condition is also referred to as "cervical dystonia". Both agonist and antagonist muscles contract simultaneously during dystonic movement. Causes of the disorder are predominantly idiopathic. A small number of patients develop the disorder as a result of another disorder or disease. Most patients first experience symptoms midlife. The most common treatment for spasmodic torticollis is the use of botulinum toxin type A.

<span class="mw-page-title-main">Meige's syndrome</span> Medical condition

Meige's syndrome is a type of dystonia. It is also known as Brueghel's syndrome and oral facial dystonia. It is actually a combination of two forms of dystonia, blepharospasm and oromandibular dystonia (OMD).

Spasmodic dysphonia, also known as laryngeal dystonia, is a disorder in which the muscles that generate a person's voice go into periods of spasm. This results in breaks or interruptions in the voice, often every few sentences, which can make a person difficult to understand. The person's voice may also sound strained or they may be nearly unable to speak. Onset is often gradual and the condition is lifelong.

<span class="mw-page-title-main">Acetyl hexapeptide-3</span> Chemical compound

Acetyl hexapeptide-8 or acetyl hexapeptide-8 amide is a synthetic anti-wrinkle cosmetics ingredient. It is a peptide which is a fragment of SNAP-25, a substrate of botulinum toxin (Botox). Acetyl hexapeptide-8 is marketed as Argireline® peptide by Lubrizol.

Myoclonic dystonia or Myoclonus dystonia syndrome is a rare movement disorder that induces spontaneous muscle contraction causing abnormal posture. The prevalence of myoclonus dystonia has not been reported, however, this disorder falls under the umbrella of movement disorders which affect thousands worldwide. Myoclonus dystonia results from mutations in the SGCE gene coding for an integral membrane protein found in both neurons and muscle fibers. Those suffering from this disease exhibit symptoms of rapid, jerky movements of the upper limbs (myoclonus), as well as distortion of the body's orientation due to simultaneous activation of agonist and antagonist muscles (dystonia).

Oromandibular dystonia(OMD) is an uncommon focal neurological condition affecting the jaws, face, and mouth. Oromandibular dystonia is characterized by involuntary spasms of the tongue, jaw, and mouth muscles that result in bruxism, or grinding of the teeth, and jaw closure. These conditions frequently lead to secondary dental wear as well as temporomandibular joint syndrome. In addition, problems with chewing, speaking, and swallowing may result from jaw opening, involuntary tongue movements, or jaw deviation.

Botulinum toxin therapy of strabismus is a medical technique used sometimes in the management of strabismus, in which botulinum toxin is injected into selected extraocular muscles in order to reduce the misalignment of the eyes. The injection of the toxin to treat strabismus, reported upon in 1981, is considered to be the first ever use of botulinum toxin for therapeutic purposes. Today, the injection of botulinum toxin into the muscles that surround the eyes is one of the available options in the management of strabismus. Other options for strabismus management are vision therapy and occlusion therapy, corrective glasses and prism glasses, and strabismus surgery.

In ophthalmology, apraxia of lid opening (ALO) is an inability to initiate voluntary opening of the eyelid following a period of eyelid closure, with normal function at other times. Manual lifting of the eyelid often resolves the problem and the lid is able to stay open.

Alan Brown Scott was an American ophthalmologist specializing in eye muscles and their disorders, such as strabismus. He is best known for his work in developing and manufacturing the drug that became known as Botox, research described as "groundbreaking" by the ASCRS.

Rachelle Smith Doody is an American neurologist and neuroscientist. She is known for her work on late stage development of drugs for Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and other neurodegenerative disorders.

Mark Hallett is an American neurologist who researched the physiology of human movement and movement disorders including functional motor disorders at the NIH, and currently serves as Distinguished NIH Investigator Emeritus. Hallett worked at NIH for 40 years in the federal government, with several decades at the Human Motor Control Section and was previously chief of the Clinical Neurophysiology Laboratory at Brigham Women's Hospital.

References

  1. ↑ Hallett, Mark (12 November 2002). "Blepharospasm: Recent advances". Neurology. 59 (9): 1306–1312. doi:10.1212/01.WNL.0000027361.73814.0E. ISSN   0028-3878. PMID   12434791.
  2. ↑ Hallett, Mark; Evinger, Craig; Jankovic, Joseph; Stacy, Mark (14 October 2008). "Update on blepharospasm". Neurology. 71 (16): 1275–1282. doi:10.1212/01.wnl.0000327601.46315.85. ISSN   0028-3878.
  3. 1 2 3 Defazio, Giovanni; Hallett, Mark; Jinnah, Hyder A.; Conte, Antonella; Berardelli, Alfredo (10 February 2017). "Blepharospasm 40 years later". Movement Disorders. 32 (4): 498–509. doi:10.1002/mds.26934. ISSN   0885-3185. PMC   5941939 . PMID   28186662.
  4. 1 2 3 4 5 6 Scorr, Laura M.; Cho, Hyun Joo; Kilic-Berkmen, Gamze; McKay, J. Lucas; Hallett, Mark; Klein, Christine; Baumer, Tobias; Berman, Brian D.; Feuerstein, Jeanne S.; Perlmutter, Joel S.; Berardelli, Alfredo; Ferrazzano, Gina; Wagle-Shukla, Aparna; Malaty, Irene A.; Jankovic, Joseph (16 May 2022). "Clinical Features and Evolution of Blepharospasm: A Multicenter International Cohort and Systematic Literature Review". Dystonia. 1. doi: 10.3389/dyst.2022.10359 . ISSN   2813-2106. PMC   9557246 . PMID   36248010.
  5. ↑ Steeves, Thomas D.; Day, Lundy; Dykeman, Jonathan; Jette, Nathalie; Pringsheim, Tamara (31 October 2012). "The prevalence of primary dystonia: A systematic review and meta-analysis". Movement Disorders. 27 (14): 1789–1796. doi:10.1002/mds.25244. ISSN   0885-3185. PMID   23114997.
  6. 1 2 Simon, Guy J. Ben; McCann, John D. (Summer 2005). "Benign Essential Blepharospasm". International Ophthalmology Clinics. 45 (3): 49–75. doi:10.1097/01.iio.0000167238.26526.a8. ISSN   0020-8167. PMID   15970766.
  7. 1 2 Byrd, Erica; Albers, Kathleen; Goldman, Samuel; Klingman, Jeffrey; Lo, Raymond; Marras, Connie; Leimpeter, Amethyst; Fross, Robin; Comyns, Kathleen; Gu, Zhuqin; Katz, Maya; Ozelius, Laurie; Bressman, Susan; Saunders-Pullman, Rachel; Comella, Cynthia (5 April 2016). "Blepharospasm in a Multiethnic Population (P3.348)". Neurology. 86 (16_supplement). doi:10.1212/wnl.86.16_supplement.p3.348. ISSN   0028-3878.
  8. 1 2 3 4 5 Sun, Yng; Tsai, Pei-Jhen; Chu, Chin-Liang; Huang, Wei-Chun; Bee, Youn-Shen (26 December 2018). "Epidemiology of benign essential blepharospasm: A nationwide population-based retrospective study in Taiwan". PLOS ONE. 13 (12): e0209558. Bibcode:2018PLoSO..1309558S. doi: 10.1371/journal.pone.0209558 . ISSN   1932-6203. PMC   6306223 . PMID   30586395.
  9. ↑ Bradley, Elizabeth A.; Hodge, David O.; Bartley, George B. (May 2003). "Benign Essential Blepharospasm Among Residents of Olmsted County, Minnesota, 1976 to 1995: An Epidemiologic Study". Ophthalmic Plastic & Reconstructive Surgery. 19 (3): 177–181. doi:10.1097/01.IOP.0000065203.88182.CF. ISSN   0740-9303. PMID   12918550.
  10. 1 2 Defazio, G.; Livrea, P.; De Salvia, R.; Manobianca, G.; Coviello, V.; Anaclerio, D.; Guerra, V.; Martino, D.; Valluzzi, F.; Liguori, R.; Logroscino, G. (12 June 2001). "Prevalence of primary blepharospasm in a community of Puglia region, Southern Italy". Neurology. 56 (11): 1579–1581. doi:10.1212/wnl.56.11.1579. ISSN   0028-3878. PMID   11402121.
  11. 1 2 3 4 5 Grandas, F; Elston, J; Quinn, N; Marsden, C D (1 June 1988). "Blepharospasm: a review of 264 patients". Journal of Neurology, Neurosurgery & Psychiatry. 51 (6): 767–772. doi:10.1136/jnnp.51.6.767. ISSN   0022-3050. PMC   1033145 . PMID   3404184.
  12. ↑ Martino, Davide; Livrea, Paolo; Giorelli, Maurizio; Masi, Gianluca; Aniello, Maria Stella; Defazio, Giovanni (2002). "Menopause and Menarche in Patients with Primary Blepharospasm: An Exploratory Case-Control Study". European Neurology. 47 (3): 161–164. doi:10.1159/000047975. ISSN   0014-3022. PMID   11914554.
  13. 1 2 Liesegang, Thomas J (March 2002). "Hormone replacement therapy and dry eye syndrome. Schaumberg DA,∗∗Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Ave E, Boston, MA 02215. USA E-mail: schaumberg@rics.bwh.harvard.edu Buring JE, Sullivan DA, Dana MR. JAMA 2001;286:2114–2119". American Journal of Ophthalmology. 133 (3): 435–436. doi:10.1016/s0002-9394(02)01368-5. ISSN   0002-9394.
  14. ↑ Adams WH, Digre KB, Patel BC, Anderson RL, Warner JE, Katz BJ (July 2006). "The evaluation of light sensitivity in benign essential blepharospasm". American Journal of Ophthalmology. 142 (1): 82–87. doi:10.1016/j.ajo.2006.02.020. PMID   16815254.
  15. ↑ Molloy, Anna; Williams, Laura; Kimmich, Okka; Butler, John S; Beiser, Ines; McGovern, Eavan; O'Riordan, Sean; Reilly, Richard B; Walsh, Cathal; Hutchinson, Michael (22 April 2015). "Sun exposure is an environmental factor for the development of blepharospasm". Journal of Neurology, Neurosurgery & Psychiatry. 87 (4): 420–424. doi:10.1136/jnnp-2014-310266. ISSN   0022-3050. PMID   25904812.
  16. 1 2 Elsron, J S; Marsden, C D; Grandas, F; Quinn, N P (July 1988). "The significance of ophthalmological symptoms in idiopathic blepharospasm". Eye. 2 (4): 435–439. doi:10.1038/eye.1988.79. ISSN   0950-222X. PMID   3253136.
  17. ↑ Defazio, Giovanni; Abbruzzese, Giovanni; Stella Aniello, Maria; Di Fede, Roberta; Esposito, Marcello; Fabbrini, Giovanni; Girlanda, Paolo; Liguori, Rocco; Marinelli, Lucio; Martino, Davide; Morgante, Francesca; Santoro, Lucio; Tinazzi, Michele; Berardelli, Alfredo (15 December 2011). "Eye symptoms in relatives of patients with primary adult-onset dystonia". Movement Disorders. 27 (2): 305–307. doi:10.1002/mds.24026. ISSN   0885-3185. PMID   22173654.
  18. 1 2 Defazio, Giovanni; Livrea, Paolo (2004). "Primary Blepharospasm". Drugs. 64 (3): 237–244. doi:10.2165/00003495-200464030-00002. ISSN   0012-6667.
  19. ↑ Martino, Davide; Liuzzi, Daniele; Macerollo, Antonella; Aniello, Maria Stella; Livrea, Paolo; Defazio, Giovanni (15 March 2010). "The phenomenology of the geste antagoniste in primary blepharospasm and cervical dystonia". Movement Disorders. 25 (4): 407–412. doi:10.1002/mds.23011. ISSN   0885-3185. PMID   20108367.
  20. ↑ Peckham, E. L.; Lopez, G.; Shamim, E. A.; Richardson, S. Pirio; Sanku, S.; Malkani, R.; Stacy, M.; Mahant, P.; Crawley, A.; Singleton, A.; Hallett, M. (17 February 2011). "Clinical features of patients with blepharospasm: a report of 240 patients". European Journal of Neurology. 18 (3): 382–386. doi:10.1111/j.1468-1331.2010.03161.x. ISSN   1351-5101. PMC   3934127 . PMID   20649903.
  21. ↑ Coscarelli, Jandira Mourão (May 2010). "Essential Blepharospasm". Seminars in Ophthalmology. 25 (3): 104–108. doi:10.3109/08820538.2010.488564. ISSN   0882-0538. PMID   20590421.
  22. ↑ Hwang, WJ (2012). "Demographic and Clinical Features of Patients with Blepharospasm in Southern Taiwan: a university Hospital-Based Study". Acta Neurol Taiwan. 21: 108–114. PMID   23196730.
  23. ↑ Marsden, C D (1 December 1976). "Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia?". Journal of Neurology, Neurosurgery & Psychiatry. 39 (12): 1204–1209. doi:10.1136/jnnp.39.12.1204. ISSN   0022-3050. PMC   492566 . PMID   1011031.
  24. ↑ Evinger, Craig; Bao, Jian-Bin; Powers, Alice S.; Kassem, Iris S.; Schicatano, Edward J.; Henriquez, Victor M.; Peshori, Kavita R. (31 January 2002). "Dry eye, blinking, and blepharospasm". Movement Disorders. 17 (S2): S75–S78. doi:10.1002/mds.10065. ISSN   0885-3185. PMC   3327285 . PMID   11836761.
  25. ↑ Conte, Antonella; Ferrazzano, Gina; Defazio, Giovanni; Fabbrini, Giovanni; Hallett, Mark; Berardelli, Alfredo (2 June 2017). "Increased Blinking May Be a Precursor of Blepharospasm: A Longitudinal Study". Movement Disorders Clinical Practice. 4 (5): 733–736. doi:10.1002/mdc3.12499. ISSN   2330-1619. PMC   5654574 . PMID   29082270.
  26. ↑ Lu, Rong; Huang, Ruisheng; Li, Kang; Zhang, Xinchun; Yang, Hui; Quan, Yadan; Li, Qian (March 2014). "The Influence of Benign Essential Blepharospasm on Dry Eye Disease and Ocular Inflammation". American Journal of Ophthalmology. 157 (3): 591–597.e2. doi:10.1016/j.ajo.2013.11.014. ISSN   0002-9394. PMID   24269849.
  27. ↑ Jankovic, Joseph; Ford, Janet (April 1983). "Blepharospasm and orofacial-cervical dystonia: Clinical and pharmacological findings in 100 patients". Annals of Neurology. 13 (4): 402–411. doi:10.1002/ana.410130406. ISSN   0364-5134. PMID   6838174.
  28. ↑ Abbruzzese, G; Berardelli, A; Girlanda, P; Marchese, R; Martino, D; Morgante, F; Avanzino, L; Colosimo, C; Defazio, G (1 April 2008). "Long-term assessment of the risk of spread in primary late-onset focal dystonia". Journal of Neurology, Neurosurgery & Psychiatry. 79 (4): 392–396. doi:10.1136/jnnp.2007.124594. ISSN   0022-3050. PMID   17635969.
  29. ↑ Micheli, Federico; Scorticati, María Clara; Folgar, Silvia; Gatto, Emilia (September 2004). "Development of Parkinson's disease in patients with blepharospasm". Movement Disorders. 19 (9): 1069–1072. doi:10.1002/mds.20084. ISSN   0885-3185. PMID   15372598.
  30. ↑ Rana, Abdul-Qayyum; Kabir, Ashish; Dogu, Okan; Patel, Ami; Khondker, Sumaiya (11 October 2012). "Prevalence of Blepharospasm and Apraxia of Eyelid Opening in Patients with Parkinsonism, Cervical Dystonia and Essential Tremor". European Neurology. 68 (5): 318–321. doi:10.1159/000341621. ISSN   0014-3022. PMID   23075668.
  31. ↑ Nociti, V; Bentivoglio, Ar; Frisullo, G; Fasano, A; Soleti, F; Iorio, R; Loria, G; Patanella, Ak; Marti, A; Tartaglione, T; Tonali, Pa; Batocchi, Ap (November 2008). "Movement disorders in multiple sclerosis: causal or coincidental association?". Multiple Sclerosis Journal. 14 (9): 1284–1287. doi:10.1177/1352458508094883. ISSN   1352-4585. PMID   18768580.
  32. ↑ Edechi, Chidalu A.; Micieli, Jonathan A. (28 April 2022). "Blepharospasm and Sixth Nerve Palsy as the Presenting Sign of Multiple Sclerosis". Journal of Neuro-Ophthalmology: 10.1097/WNO.0000000000001916. doi:10.1097/WNO.0000000000001916. ISSN   1070-8022.
  33. 1 2 Wakakura M, Tsubouchi T, Inouye J (March 2004). "Etizolam and benzodiazepine induced blepharospasm". Journal of Neurology, Neurosurgery, and Psychiatry. 75 (3): 506–507. doi:10.1136/jnnp.2003.019869. PMC   1738986 . PMID   14966178.
  34. 1 2 Wakakura, M.; Yamagami, A.; Iwasa, M. (3 September 2018). "Blepharospasm in Japan: A Clinical Observational Study From a Large Referral Hospital in Tokyo". Neuro-Ophthalmology. 42 (5): 275–283. doi:10.1080/01658107.2017.1409770. ISSN   0165-8107. PMC   6152494 . PMID   30258472.
  35. ↑ Mauriello, Joseph A.; Carbonaro, Paul; Dhillon, Shamina; Leone, Tina; Franklin, Mark (June 1998). "Drug-Associated Facial Dyskinesias—A Study of 238 Patients". Journal of Neuro-Ophthalmology. 18 (2): 153. doi:10.1097/00041327-199806000-00016. ISSN   1070-8022. PMID   9621275.
  36. ↑ Martino, Davide; Defazio, Giovanni; Abbruzzese, Giovanni; Girlanda, Paolo; Tinazzi, Michele; Fabbrini, Giovanni; Aniello, Maria Stella; Avanzino, Laura; Colosimo, Carlo; Majorana, Giuseppe; Trompetto, Carlo (March 2007). "Head trauma in primary cranial dystonias: a multicentre case–control study". Journal of Neurology, Neurosurgery, and Psychiatry. 78 (3): 260–263. doi:10.1136/jnnp.2006.103713. ISSN   0022-3050. PMC   2117628 . PMID   17056625.
  37. ↑ Molloy, Anna; Williams, Laura; Kimmich, Okka; Butler, John S.; Beiser, Ines; McGovern, Eavan; O'Riordan, Sean; Reilly, Richard B.; Walsh, Cathal; Hutchinson, Michael (1 April 2016). "Sun exposure is an environmental factor for the development of blepharospasm". Journal of Neurology, Neurosurgery & Psychiatry. 87 (4): 420–424. doi:10.1136/jnnp-2014-310266. ISSN   0022-3050. PMID   25904812.
  38. ↑ Defazio, Giovanni; Hallett, Mark; Jinnah, Hyder A.; Berardelli, Alfredo (16 July 2013). "Development and validation of a clinical guideline for diagnosing blepharospasm". Neurology. 81 (3): 236–240. doi:10.1212/wnl.0b013e31829bfdf6. ISSN   0028-3878. PMC   3770163 . PMID   23771487.
  39. ↑ Defazio, Giovanni; Jinnah, Hyder A.; Berardelli, Alfredo; Perlmutter, Joel S.; Berkmen, Gamze Kilic; Berman, Brian D.; Jankovic, Joseph; Bäumer, Tobias; Comella, Cynthia; Cotton, Adam C.; Ercoli, Tommaso; Ferrazzano, Gina; Fox, Susan; Kim, Han-Joon; Moukheiber, Emile Sami (October 2021). "Diagnostic criteria for blepharospasm: A multicenter international study". Parkinsonism & Related Disorders. 91: 109–114. doi:10.1016/j.parkreldis.2021.09.004. ISSN   1353-8020. PMC   9048224 . PMID   34583301.
  40. 1 2 Vijayakumar, Dhanya; Jankovic, Joseph (4 July 2018). "Medical treatment of blepharospasm". Expert Review of Ophthalmology. 13 (4): 233–243. doi:10.1080/17469899.2018.1503535. ISSN   1746-9899.
  41. ↑ Nutt, John G.; Hammerstad, John P.; de Garmo, Pat; Carter, Julie (February 1984). "Cranial dystonia: Double-blind crossover study of anticholinergics". Neurology. 34 (2): 215–217. doi:10.1212/WNL.34.2.215. ISSN   0028-3878. PMID   6363970.
  42. ↑ Piyasena INAP; Jayasinghe JAC (March 2014). "Mosapride (5HT4 agonist) in the treatment of blepharospasm". Ceylon Med J. 59 (1): 26–27. doi: 10.4038/cmj.v59i1.5527 . PMID   24682196.
  43. 1 2 Duarte, Gonçalo S; Rodrigues, Filipe B; Marques, Raquel E; Castelão, Mafalda; Ferreira, Joaquim; Sampaio, Cristina; Moore, Austen P; Costa, João (19 November 2020). Cochrane Movement Disorders Group (ed.). "Botulinum toxin type A therapy for blepharospasm". Cochrane Database of Systematic Reviews. 2020 (11): CD004900. doi:10.1002/14651858.CD004900.pub3. PMC   8094161 . PMID   33211907.
  44. ↑ Simpson, D. M.; Hallett, M.; Ashman, E. J.; Comella, C. L.; Green, M. W.; Gronseth, G. S.; Armstrong, M. J.; Gloss, D.; Potrebic, S.; Jankovic, J.; Karp, B. P.; Naumann, M.; So, Y. T.; Yablon, S. A. (18 April 2016). "Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology". Neurology. 86 (19): 1818–1826. doi:10.1212/WNL.0000000000002560. PMC   4862245 . PMID   27164716.
  45. ↑ Ababneh, Osama H; Cetinkaya, Altug; Kulwin, Dwight R (April 2014). "Long‐term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm". Clinical & Experimental Ophthalmology. 42 (3): 254–261. doi:10.1111/ceo.12165. ISSN   1442-6404.
  46. ↑ Anderson RL, Patel BC, Holds JB, Jordan DR (September 1998). "Blepharospasm: past, present, and future". Ophthalmic Plastic and Reconstructive Surgery. 14 (5): 305–317. doi:10.1097/00002341-199809000-00002. PMID   9783280. S2CID   13678666.
  47. ↑ Fantato, Alexina; Parulekar, Manoj; Elston, John (2 July 2019). "A trial of a mechanical device for the treatment of blepharospasm". Eye. 33 (11): 1803–1808. doi:10.1038/s41433-019-0495-y. ISSN   0950-222X.
  48. ↑ Uchida, Kazuko; Kiyosawa, Motohiro; Wakakura, Masato (2020). "Efficacy of a Non-invasive Cosmetic Forcible Trick Treatment for Blepharospasm: Increase in Quality of Life Due to Use of Ultra-thin Adhesive Tape". NeuroOphthalmology Japan. 37 (2): 237–243. doi:10.11476/shinkeiganka.37.237 – via JStage.
  49. ↑ Farias, Joaquin (2016). Limitless. How your movements can heal your brain: An essay on the neurodynamics of dystonia. Galene Editions. ISBN   978-0-9951701-0-0.
  50. ↑ Farias, J., Sarti-Martínez, MA. Title: "Elite musicians treated by specific fingers motion program to stimulate propiceptive sense", Congreso Nacional De La Sociedad Anatómica Española, Alicante (España), European Journal of Anatomy, p. 110

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.